Eisai Co (ESALF) Gets a Hold from Jefferies
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Barker is a 2-star analyst with an average return of 1.4% and a 44.12% success rate. Barker covers the Healthcare sector, focusing on stocks such as Sumitomo Dainippon Pharma Co, Astellas Pharma, and Asahi Intecc Co.
Currently, the analyst consensus on Eisai Co is a Moderate Buy with an average price target of $35.06.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Nike Stock Keeps Rising. Caitlin Clark Is Helping
Nike shares are continuing their post-earnings rally Tuesday, aided by the company's release of a sneaker in collaboration with WNBA superstar Caitlin Clark. Nike stock is now up 17% from where it closed Thursday, when the brand released results that topped expectations. Shares still may have room to grow as the brand focuses on tapping demand for women's sportswear and shoes, Jefferies fever hasn't broken. Shares of the sneaker giant extended their post-earnings climb with a 3% advance Tuesday, a day after the company released a shoe with WNBA superstar Caitlin Clark. The $190 sneakers—featuring colors that reference the guard's Indiana Fever jersey—"instantly" sold out, Jefferies wrote in a research note Monday. After markets closed last Thursday, Nike (NKE) reported fourth-quarter results that beat analysts' expectations. Shares soared 15% Friday and—after ending 1% lower yesterday—resumed their ascent Tuesday, with Jefferies analysts noting that "buzz" about the shoes suggests that shares may still have room to grow. The brand is tapping into the burgeoning women's sportswear market, the analysts said, and after releasing a new Kobe V prototype with Clark, Nike and the WNBA star are planning an "upcoming signature shoe release [that] could be even more impactful." "Nike's latest moves signal a bold bet on women, tapping into one of its fastest-growing segments within sport and unlocking fresh upside across its [8-billion-person total addressable market]," Jefferies wrote. Women's basketball is becoming increasingly popular, with Jefferies noting WNBA viewership jumped 31% year-over-year and game attendance soared 48% in 2024. Women's shoes and sportswear sales are expected to outpace men's over the next five years, it added. Jefferies has a $115 price target on Nike stock, well above the $77 average among analysts covering it tracked by Visible Alpha. Shares are trading around $73 Tuesday afternoon, and remain down 3.5% this year as the brand mounts a turnaround campaign. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business Wire
Moelis Appoints Thorold Barker as an Independent Member to its Board of Directors
NEW YORK--(BUSINESS WIRE)--Moelis & Company (NYSE: MC), a leading global independent investment bank, today announced the appointment of Thorold Barker to its Board of Directors, effective July 1, 2025. Mr. Barker brings over 30 years of experience across journalism, finance, and geopolitics. He most recently served as The Wall Street Journal's Editor for Europe, Middle East and Africa for 10 years, during the European debt crisis, Brexit, the COVID-19 pandemic, and the start of the Russia-Ukraine conflict. Mr. Barker was also the Masthead Editor overseeing the Journal's global events, including the CEO Council. Mr. Barker joined the paper in New York in 2008, as Editor of Heard on the Street, the publication's commentary and analysis column covering business and finance. Earlier in his career, Mr. Barker was the U.S. Editor of the Lex Column and a reporter at the Financial Times. He started his career as a strategy consultant at Bain & Company. Ken Moelis, Chairman and CEO of Moelis & Company commented, 'Thorold brings a unique perspective shaped by his global experience across business, media, and policy, which makes him a valuable addition to our Board. We are delighted to welcome him.' Mr. Barker will join Moelis's Board as an Independent Director, serving alongside Dr. Louise Mirrer, Kenneth Shropshire, and Laila Worrell. Mr. Barker is currently a Senior Adviser at AlixPartners, serves as a visiting fellow at the University of Oxford, and sits on the board of Tiger21. He holds a degree in Modern Languages from Trinity College, Cambridge. About Moelis & Company Moelis & Company ('Moelis') is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis's experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. The Firm serves clients from locations across North and South America, Europe, the Middle East, and Asia-Pacific. For further information, please visit:
Business Insider
16 hours ago
- Business Insider
UBS Reaffirms Their Buy Rating on Symrise (0G6T)
In a report released today, Charles Eden from UBS maintained a Buy rating on Symrise (0G6T – Research Report), with a price target of €115.00. The company's shares closed yesterday at €89.14. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Eden covers the Consumer Defensive sector, focusing on stocks such as Givaudan SA, Symrise, and Kerry Group plc. According to TipRanks, Eden has an average return of -0.4% and a 48.06% success rate on recommended stocks. Currently, the analyst consensus on Symrise is a Moderate Buy with an average price target of €114.91, implying a 28.91% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a €120.00 price target.
